LEADER 04393nam 22007215 450 001 9910300216803321 005 20200703162709.0 010 $a1-4939-2143-6 024 7 $a10.1007/978-1-4939-2143-0 035 $a(CKB)3710000000291388 035 $a(EBL)1968105 035 $a(OCoLC)908088491 035 $a(SSID)ssj0001385815 035 $a(PQKBManifestationID)11752089 035 $a(PQKBTitleCode)TC0001385815 035 $a(PQKBWorkID)11348940 035 $a(PQKB)10519743 035 $a(DE-He213)978-1-4939-2143-0 035 $a(MiAaPQ)EBC1968105 035 $a(PPN)183097548 035 $a(EXLCZ)993710000000291388 100 $a20141124d2015 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aBRAF Targets in Melanoma$b[electronic resource] $eBiological Mechanisms, Resistance, and Drug Discovery /$fedited by Ryan J. Sullivan 205 $a1st ed. 2015. 210 1$aNew York, NY :$cSpringer New York :$cImprint: Humana,$d2015. 215 $a1 online resource (206 p.) 225 1 $aCancer Drug Discovery and Development,$x2196-9906 ;$v82 300 $aDescription based upon print version of record. 311 $a1-4939-2142-8 320 $aIncludes bibliographical references at the end of chapters and index. 327 $aMelanoma: Historical Context -- Melanoma Pathogenesis -- Molecular Diagnostics and Tumor Mutational Analysis -- Clinical Utility of BRAF-targeted therapy in Melanoma -- The Ethics of Randomized Trials in Oncology -- Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma -- Targeting the cell cycle and p53 in combination with BRAF-directed therapy -- Combination BRAF-directed therapy and immunotherapy -- Moving Forward: Making BRAF-Targeted Therapy Better. 330 $aThis volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that these drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted cancer agents. Namely, the identification of a molecular target, the selection of molecules which effectively inhibit this target. What is starkly different about the development of this class of compounds, however, is that the mechanism of action of these agents are not as straightforward as was once previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other types of molecules could be used in combination with BRAF-inhibitors in hopes of revolutionizing the potential of therapeutics in melanoma. 410 0$aCancer Drug Discovery and Development,$x2196-9906 ;$v82 606 $aCancer research 606 $aMolecular biology 606 $aMedical microbiology 606 $aPharmacology 606 $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001 606 $aMolecular Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/B1700X 606 $aMedical Microbiology$3https://scigraph.springernature.com/ontologies/product-market-codes/B16003 606 $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007 615 0$aCancer research. 615 0$aMolecular biology. 615 0$aMedical microbiology. 615 0$aPharmacology. 615 14$aCancer Research. 615 24$aMolecular Medicine. 615 24$aMedical Microbiology. 615 24$aPharmacology/Toxicology. 676 $a616.9947706 702 $aSullivan$b Ryan J$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910300216803321 996 $aBRAF Targets in Melanoma$91760486 997 $aUNINA